ODOMZO® (Sonidegib)

The FDA on July 24, 2015 approved ODOMZO® for the treatment of patients with locally advanced Basal Cell Carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO® capsules are a product of Novartis Pharmaceuticals Corporation